148
Views
1
CrossRef citations to date
0
Altmetric
Rapid Communication

Efficacy, safety, and pharmacokinetics of once-daily boosted darunavir in pretreated HIV-infected patients

, , , , , , , , & show all
Pages 407-410 | Received 13 Sep 2012, Accepted 15 Nov 2012, Published online: 11 Mar 2013
 

Abstract

Objective and methods: The efficacy and safety of switching to a combined regimen containing darunavir/ritonavir (DRV/r) was investigated in a retrospective study. Results: Sixty-six experienced patients receiving once-daily DRV/r (900/100 mg) in various regimens were included (median age 51 y; male 82%; Centers for Disease Control and Prevention (CDC) stages B or C 70%). The number of patients with plasma HIV RNA < 50 copies/ml increased from 71% (45/63) at baseline (before switch) to 84% (52/62) at visit 1 (weeks 3–11), and to 92% (60/65) at visit 2 (weeks 12–24). CD4 cells increased from 498 ± 201 cells/mm3 at baseline to 567 ± 232 cells/mm3 by visit 2. Good digestive and metabolic tolerance was observed. The median steady-state DRV plasma concentration, measured 24 ± 4 h after the last drug intake, was 1427 ng/ml. All DRV plasma concentrations were above the protein-binding corrected median effective concentration (EC50) for the wild-type virus (55 ng/ml). Conclusions: Once-daily DRV/r (900/100 mg) was efficacious in pretreated patients, with safe responses.

Acknowledgements

The authors would like to thank Dr F. Sordet, Janssen Laboratories for helpful contributions to our discussions and Newmed Publishing Services for technical editing of the final manuscript without charge.

Declaration of interest:

Neither the study nor its follow-up and analysis were funded. All follow- up and analysis was conducted by the Institut de Médecine et d’Epidémiologie Appliquée in Paris.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 174.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.